TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15008770

Group type: EXPERIMENTAL
Intervention: Preclosure analgesia (saline before incision and lignocaine before closure)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Preemptive analgesia (lignocaine before incision and saline before closure)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (saline before incision and closure)
Number of subjects: 144
Study: 12638834

Group type: EXPERIMENTAL
Intervention: 24‐gauge Gertie Marx needle
Number of subjects: 60

Group type: COMPARATOR
Intervention: 25‐gauge Quincke needle
Number of subjects: 60
Study: 9588720

Group type: EXPERIMENTAL
Intervention: Elective lymph node dissection (ELND)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lymphatic mapping with sentinel lymph node biopsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (routine care without ELND)
Number of subjects: 0
Study: 8813312

Group type: EXPERIMENTAL
Intervention: Depot-medroxyprogesterone acetate (DMPA)
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Higher parity
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 910

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 910
Study: 2299491

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 41
Study: 7235806

Group type: EXPERIMENTAL
Intervention: Percussion measurement of diaphragmatic excursion
Number of subjects: 29
Study: 29357754

Group type: EXPERIMENTAL
Intervention: Patient-initiated euthanasia for cancer or depression
Number of subjects: 324

Group type: COMPARATOR
Intervention: Family-initiated euthanasia for cancer or depression
Number of subjects: 324

Group type: COMPARATOR
Intervention: Euthanasia attitudes for schizophrenia
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Attitudes toward euthanasia based on illness type
Number of subjects: 324
Study: 31584919

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygenation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional facemask oxygenation
Number of subjects: 40
Study: 28483629

Group type: EXPERIMENTAL
Intervention: DACC-coated postoperative dressings
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional dressings
Number of subjects: 200
Study: 25330734

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 196
Study: 24903195

Group type: EXPERIMENTAL
Intervention: Intra-aortic Balloon Pump (IABP) therapy
Number of subjects: 190

Group type: COMPARATOR
Intervention: No IABP therapy (Control)
Number of subjects: 190
Study: 21868369

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard management alone
Number of subjects: 20
Study: 20371445

Group type: EXPERIMENTAL
Intervention: ESHAP (etoposide, methylprednisolone, cytosine arabinoside, and platinum)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: R-ESHAP (rituximab plus ESHAP)
Number of subjects: 100
Study: 17442202

Group type: EXPERIMENTAL
Intervention: Diver CE device
Number of subjects: 122

Group type: COMPARATOR
Intervention: Guardwire Plus device
Number of subjects: 122
Study: 15803031

Group type: COMPARATOR
Intervention: Infliximab (maintenance therapy)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Infliximab (first dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Infliximab (combined groups)
Number of subjects: 10
Study: 11943119

Group type: EXPERIMENTAL
Intervention: error+correct training
Number of subjects: 30

Group type: COMPARATOR
Intervention: correct only training
Number of subjects: 30

Group type: COMPARATOR
Intervention: error only training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: error training for faculty raters
Number of subjects: 30

Group type: COMPARATOR
Intervention: no training for faculty raters
Number of subjects: 30
Study: 10567780

Group type: EXPERIMENTAL
Intervention: Gemifloxacin (320 mg once daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (matched)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Comparison of gemifloxacin vs placebo
Number of subjects: 35
Study: 7848022

Group type: EXPERIMENTAL
Intervention: Cholestyramine resin, 8 g/d
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cholestyramine resin, 8 g/d plus lovastatin, 5 mg/d
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lovastatin, 20 mg/d
Number of subjects: 26
Study: 2179146

Group type: EXPERIMENTAL
Intervention: Dietary weight loss
Number of subjects: 31

Group type: COMPARATOR
Intervention: Endurance exercise training
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 343795

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reserpine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31764336

Group type: EXPERIMENTAL
Intervention: Cough trick during drain removal
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual process without cough trick
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cough trick
Number of subjects: 56
Study: 27914839

Group type: EXPERIMENTAL
Intervention: IOL repositioning by scleral suturing (n = 54)
Number of subjects: 104

Group type: COMPARATOR
Intervention: IOL exchange with retropupillary fixation of an iris-claw IOL (n = 50)
Number of subjects: 104
Study: 26048388

Group type: EXPERIMENTAL
Intervention: Eccentricity index measured from pre‐procedural CT/MR imaging
Number of subjects: 38
Study: 24156137

Group type: EXPERIMENTAL
Intervention: 1.5% arginine and 1450 ppm fluoride as sodium monofluorophosphate in a calcium base (experimental)
Number of subjects: 412

Group type: COMPARATOR
Intervention: 1450 ppm fluoride as sodium fluoride in a silica base (positive control)
Number of subjects: 412

Group type: COMPARATOR
Intervention: No fluoride in a calcium base (negative control)
Number of subjects: 412
Study: 21560649

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative anti-inflammatory drug based on ginger extract
Number of subjects: 0
Study: 19399932

Group type: EXPERIMENTAL
Intervention: Case A (shorter and almost straight duodenal section)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case B (longer and curved duodenal section)
Number of subjects: 0
Study: 16721468

Group type: EXPERIMENTAL
Intervention: Chemomechanical method (Carisolv)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hand excavation
Number of subjects: 30
Study: 15003074

Group type: EXPERIMENTAL
Intervention: Lamotrigine (100-500 mg/day)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 11136631

Group type: EXPERIMENTAL
Intervention: Psychoanalytically oriented partial hospitalization program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard psychiatric care
Number of subjects: 44
Study: 9779760

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment with bacteriologic eradication
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment without bacteriologic eradication
Number of subjects: 123
Study: 9676769

Group type: EXPERIMENTAL
Intervention: Tramadol (250 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tramadol (50-100 mg every 4-6 h as needed for pain)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2561281

Group type: EXPERIMENTAL
Intervention: Fentanyl (F)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Naloxone (N)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline solution (S)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Initial control (C)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Final control (C')
Number of subjects: 50
Study: 54740

Group type: EXPERIMENTAL
Intervention: Laundering and vacuum-cleaning bedclothes and pillows, applying a plastic cover to the mattress for six weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 32
Study: 30952531

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (ET) including mechanical thrombectomy (MT) alone (N = 269), MT ± thrombolysis (N = 297), and thrombolysis alone (N = 682)
Number of subjects: 49952

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 49952
Study: 27872067

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 333
Study: 26121495

Group type: EXPERIMENTAL
Intervention: d-cycloserine (DCS) 50 mg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 23926685

Group type: EXPERIMENTAL
Intervention: NGN decoction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (testosterone undecanoate capsules)
Number of subjects: 60
Study: 20619411

Group type: EXPERIMENTAL
Intervention: Nursing guideline 'depression in dementia' introduced on experimental wards
Number of subjects: 193

Group type: COMPARATOR
Intervention: Usual care provided on control wards
Number of subjects: 193
Study: 19299427

Group type: EXPERIMENTAL
Intervention: Candesartan alone
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Enalapril alone
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Candesartan plus enalapril
Number of subjects: 392
Study: 16952675

Group type: EXPERIMENTAL
Intervention: 0.8 mg tamsulosin daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10 mg alfuzosin daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15459134

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0
Study: 11735088

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate alone (Cr; n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Creatine plus resistance training (Cr-RT; n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo plus resistance training (P-RT; n = 10)
Number of subjects: 30
Study: 9131726

Group type: EXPERIMENTAL
Intervention: Doxepin administered intravenously (125 mg) switched to oral administration (250 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 0
Study: 7641549

Group type: EXPERIMENTAL
Intervention: Laparoscopic treatment (totally pre-peritoneal approach)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Shouldice operation
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Laparoscopic treatment
Number of subjects: 124
Study: 2567717

Group type: EXPERIMENTAL
Intervention: Progesterone vaginal suppositories (PVS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bromocriptine (BCT)
Number of subjects: 100
Study: 31144430

Group type: EXPERIMENTAL
Intervention: acarbose 50 mg for 1 week
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg for 1 week
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: verapamil 120 mg for 1 week
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: liraglutide 1.2 mg for 3 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: pasireotide 300 μg as a single dose
Number of subjects: 11

Group type: COMPARATOR
Intervention: baseline period without treatment
Number of subjects: 11
Study: 28608641

Group type: EXPERIMENTAL
Intervention: Intensive immunosuppressive regimen (including ATG, steroid therapy, high CNI doses)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (standard immunosuppressive regimen)
Number of subjects: 105
Study: 25503377

Group type: EXPERIMENTAL
Intervention: Exposure to anti-POS advertising
Number of subjects: 0
Study: 23416811

Group type: EXPERIMENTAL
Intervention: Platelet concentrate transfusion
Number of subjects: 42
Study: 21526229

Group type: EXPERIMENTAL
Intervention: Daily micronutrient-rich nutritional supplement
Number of subjects: 2799

Group type: EXPERIMENTAL
Intervention: Two 1-hour physical activity classes per week
Number of subjects: 2799

Group type: EXPERIMENTAL
Intervention: Both interventions (nutritional supplement and physical activity)
Number of subjects: 2799

Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 2799
Study: 18843004

Group type: EXPERIMENTAL
Intervention: Soy protein intake containing 99 mg isoflavones daily
Number of subjects: 202

Group type: COMPARATOR
Intervention: Milk protein (placebo)
Number of subjects: 202
Study: 17057564

Group type: EXPERIMENTAL
Intervention: Low-frequency TENS (4 Hz, 200 micros)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High-frequency TENS (110 Hz, 200 micros)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 90
Study: 12633642

Group type: EXPERIMENTAL
Intervention: Electroanatomical mapping (CARTO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional fluoroscopic mapping
Number of subjects: 20
Study: 11140145

Group type: EXPERIMENTAL
Intervention: Multi-strategic group program (18 weeks, 2 meetings per week, 1.5 hours each) including physical exercises, psychomusical techniques, cognitive games, and tasks related to IADL
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 11
Study: 8759268

Group type: EXPERIMENTAL
Intervention: Sulphapyridine 500 mg twice daily
Number of subjects: 20
Study: 1467453

Group type: EXPERIMENTAL
Intervention: Procaterol 25 micrograms
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Procaterol 50 micrograms
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Procaterol 75 micrograms
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Procaterol 100 micrograms
Number of subjects: 14
Study: 10274896

Group type: EXPERIMENTAL
Intervention: Minimal-contact smoking cessation intervention (brief consultation, self-help manual, incentive)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Minimal-contact smoking cessation intervention
Number of subjects: 213
Study: 31068395

Group type: EXPERIMENTAL
Intervention: Boot Camp Translation (BCT) approach for refining colon cancer screening messages
Number of subjects: 25
Study: 28838010

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (O2) at 10 L/min via facemask
Number of subjects: 70

Group type: COMPARATOR
Intervention: Room air (RA)
Number of subjects: 70
Study: 27412188

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 638

Group type: COMPARATOR
Intervention: Control (discontinue all hypertensive medications)
Number of subjects: 638
Study: 25262306

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention based on the Chronic Care Model, Stanford Expert Patient Programme, and Kaiser Permanente model.
Number of subjects: 1606

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 1606
Study: 22464031

Group type: EXPERIMENTAL
Intervention: Resilience training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pragmatic training (Control)
Number of subjects: 80
Study: 20219292

Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (OMPH)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Change in desire to smoke
Number of subjects: 253
Study: 18923311

Group type: EXPERIMENTAL
Intervention: Manual physical therapy and exercise (MTE)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Minimal intervention (MIN)
Number of subjects: 94
Study: 16092046

Group type: EXPERIMENTAL
Intervention: Single bout of exercise (30 minutes)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Multiple bouts of exercise (3 x 10 minutes)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control day (no exercise)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (6 women, 49 +/- 4 years old)
Number of subjects: 9
Study: 12519101

Group type: EXPERIMENTAL
Intervention: Quetiapine therapy
Number of subjects: 17
Study: 10355619

Group type: EXPERIMENTAL
Intervention: Video instruction (VN)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Written instructions (NV)
Number of subjects: 24
Study: 7769807

Group type: EXPERIMENTAL
Intervention: Enalaprilat 0.25 mg/h
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Enalaprilat 0.5 mg/h
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 45
Study: 2022712

Group type: EXPERIMENTAL
Intervention: Loxiglumide (22 mumol/kg.h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 10-amino acid mixture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCK octapeptide (CCK-8) at 8.6 pmol/kg.h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCK-8 with loxiglumide
Number of subjects: 0
Study: 7066166

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31597046

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (200,000 IU)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31914294

Group type: EXPERIMENTAL
Intervention: 3D printing combined with three-dimensional reconstruction operation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional operation
Number of subjects: 40
Study: 28919328

Group type: COMPARATOR
Intervention: C-peptide levels (0–33%)
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: C-peptide levels (34–66%)
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: C-peptide levels (67–90%)
Number of subjects: 1263

Group type: EXPERIMENTAL
Intervention: C-peptide levels (> 90%)
Number of subjects: 1263
Study: 26281178

Group type: EXPERIMENTAL
Intervention: Livodexa (Sun Pharmaceutical Industries Ltd, India)
Number of subjects: 68
Study: 24253247

Group type: EXPERIMENTAL
Intervention: Atazanavir plus ritonavir (ATV/r) with abacavir/lamivudine (ABC/3TC)
Number of subjects: 1857

Group type: EXPERIMENTAL
Intervention: Atazanavir plus ritonavir (ATV/r) with tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 1857

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) with abacavir/lamivudine (ABC/3TC)
Number of subjects: 1857

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) with tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 1857

Group type: EXPERIMENTAL
Intervention: Atazanavir plus ritonavir (ATV/r)
Number of subjects: 1857

Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 1857
Study: 22118480

Group type: EXPERIMENTAL
Intervention: Elastic stable intramedullary nailing (ESIN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ESIN
Number of subjects: 60
Study: 19117055

Group type: COMPARATOR
Intervention: Low seropositivity for T. vaginalis (21.5% of cases, 24.8% of controls)
Number of subjects: 18882

Group type: COMPARATOR
Intervention: High seropositivity for T. vaginalis (15.2% of cases, 15.0% of controls)
Number of subjects: 18882
Study: 17329991

Group type: EXPERIMENTAL
Intervention: High-dose simvastatin
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 15137184

Group type: EXPERIMENTAL
Intervention: Stepped counseling intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 11800440

Group type: EXPERIMENTAL
Intervention: Silica coating + silanating (CO)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Roughening with a silicon carbide bur (SC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hydrofluoric acid etching for 15 s + silanating (HF)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Without treatment (WT)
Number of subjects: 120
Study: 9890203

Group type: EXPERIMENTAL
Intervention: Phenylephrine 0.5 microg/min
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Phenylephrine 1.0 microg/min
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Isoproterenol, acetylcholine, and nitroglycerin (dosage not specified)
Number of subjects: 22
Study: 7905097

Group type: EXPERIMENTAL
Intervention: Bone marrow infusion after a 10 day course of antithymocyte globulin, 5 days post-transplantation.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not specified what treatment they received).
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bone marrow infusion group.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 25
Study: 3191090

Group type: EXPERIMENTAL
Intervention: 0.2% (w/v) chlorhexidine gluconate
Number of subjects: 324

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 324

Group type: COMPARATOR
Intervention: No irrigation
Number of subjects: 324
Study: 29597051

Group type: EXPERIMENTAL
Intervention: Pulmonary artery pulsatility index (PAPi)
Number of subjects: 190
Study: 27048197

Group type: EXPERIMENTAL
Intervention: Web-based monitoring
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: FENO-based monitoring
Number of subjects: 272

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 272
Study: 25700006

Group type: EXPERIMENTAL
Intervention: Computer-delivered intervention tailored to drinking motives, profile-specific online training for 4 weeks
Number of subjects: 124

Group type: COMPARATOR
Intervention: Profile-specific feedback only (Control)
Number of subjects: 124
Study: 23917673

Group type: EXPERIMENTAL
Intervention: Methadone (5 mg bid)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 20945819

Group type: EXPERIMENTAL
Intervention: Laser vaporization plus Pidotimod and vitamin C for 2 1/2 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Laser vaporization alone
Number of subjects: 62
Study: 19035101

Group type: EXPERIMENTAL
Intervention: TACE + HITT therapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: TACE + PEI only therapy
Number of subjects: 65
Study: 17234829

Group type: EXPERIMENTAL
Intervention: Speed of processing intervention
Number of subjects: 2802

Group type: EXPERIMENTAL
Intervention: Memory intervention
Number of subjects: 2802

Group type: EXPERIMENTAL
Intervention: Reasoning intervention
Number of subjects: 2802

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 2802